Digital pathology can efficiently assess immunohistochemistry (IHC) data on tissue microarrays (TMAs). Yet, it remains important to evaluate the comparability of the data acquired by different software applications and validate it against pathologist manual interpretation. In this study, we compared the IHC quantification of 5 clinical breast cancer biomarkers—estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin 5/6 (CK5/6)—across 3 software applications (Definiens Tissue Studio, inForm, and QuPath) and benchmarked the results to pathologist manual scores.IHC expression for each marker was evaluated across 4 TMAs consisting of 935 breast...
PURPOSE Decades of quality control efforts have raised the standards of immunohistochemistry (IHC...
BACKGROUNDAnalysis of immunohistochemical expression of a large number of tumor tissue samples with ...
The determination of tumor cell estrogen receptor (ER) expression status by immunohistochemical anal...
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individu...
BackgroundTissue microarrays (TMAs) have become a valuable resource for biomarker expression in tran...
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individu...
Introduction. Accurate evaluation of estrogen and progesterone receptors and HER2 is critical when d...
Abstract: The current treatment of breast cancer, the most frequent malignancy found in females, req...
Background: Tissue microarrays (TMAs) are an attractive alternative to analysis of whole sections (W...
BACKGROUND: High-throughput evaluation of tissue biomarkers in oncology has been greatly accelerated...
Copyright © 2014 Sas Leen et al.This is an open access article distributed under the Creative Common...
Evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) is subject ...
Abstract Immunohistochemical (IHC) assays performed on formalin-fixed paraffin-embedded (FFPE) tissu...
Aims: To compare visual and computerized image analysis of HER2 immunohistochemistry (IHC) with fluo...
Breast Cancer is one of the most common cancer among women today. During their lifetime, about 1 in ...
PURPOSE Decades of quality control efforts have raised the standards of immunohistochemistry (IHC...
BACKGROUNDAnalysis of immunohistochemical expression of a large number of tumor tissue samples with ...
The determination of tumor cell estrogen receptor (ER) expression status by immunohistochemical anal...
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individu...
BackgroundTissue microarrays (TMAs) have become a valuable resource for biomarker expression in tran...
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individu...
Introduction. Accurate evaluation of estrogen and progesterone receptors and HER2 is critical when d...
Abstract: The current treatment of breast cancer, the most frequent malignancy found in females, req...
Background: Tissue microarrays (TMAs) are an attractive alternative to analysis of whole sections (W...
BACKGROUND: High-throughput evaluation of tissue biomarkers in oncology has been greatly accelerated...
Copyright © 2014 Sas Leen et al.This is an open access article distributed under the Creative Common...
Evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) is subject ...
Abstract Immunohistochemical (IHC) assays performed on formalin-fixed paraffin-embedded (FFPE) tissu...
Aims: To compare visual and computerized image analysis of HER2 immunohistochemistry (IHC) with fluo...
Breast Cancer is one of the most common cancer among women today. During their lifetime, about 1 in ...
PURPOSE Decades of quality control efforts have raised the standards of immunohistochemistry (IHC...
BACKGROUNDAnalysis of immunohistochemical expression of a large number of tumor tissue samples with ...
The determination of tumor cell estrogen receptor (ER) expression status by immunohistochemical anal...